In the first quarter of 2008, Nycomed’s adjusted EBITDA increased by 6.2% to € 304.0 million compared to € 286.3 million in the first quarter of 2007, benefiting from the cost decreasing effects of last year's restructuring. Most of Nycomed's markets and key products have performed well for the first quarter of 2008 and provided a counterweight to the decreasing sales of Pantoprazole in the US.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments